Clinical trials – Wrocław, Poland

Site by Penta Hospitals Clinic at ul. Wejherowska

Is a continuation of activities by specialized sites previously located at ul. Łowiecka and ul. Pilczycka. This allows for the continuity of experience which we have been gaining uninterrupted since 2005, offering patients and sponsors the same, proven work quality in a modern space of higher quality and better diagnostic, clinical, and research infrastructure. In this time, we have executed ca. 200 research projects regarding new therapies, and we are currently conducting over 50 active clinical trial protocols. High quality of our operations is proven with numerous positive sponsor audits and many years of cooperation with leading pharmaceutical companies.

Our main therapeutic areas, in which we have specific research experience, include:

  • Gastroenterology – diagnostics and treatment of digestive system diseases, including stomach, intestines, pancreas, and liver diseases.
  • Urology – complex care in the area of genitourinary diseases.
  • Dermatology – advanced therapies of skin diseases and esthetic dermatology procedures.
  • Otorhinolaryngology – treatment of nose, throat, larynx, and ear diseases.
  • Infectious diseases – diagnostics and therapy of viral, bacterial, and sexually-transmitted diseases.

What is more, we are also experienced in conducting trials in the following disciplines: diabetologyneurologyallergologymetabolic diseasespediatricsgynecology, and sleeping disorders.

Thanks to combining the research activity with an extensive diagnostic and specialized infrastructure (primary health care and outpatient care) we can offer our patients access to innovative therapies, which have often not been unavailable in standard treatment yet.

Badania kliniczne - Wrocław Wejherowska | Penta Hospitals Badania Kliniczne

Address:

ul. Wejherowska 28
54-239 Wrocław
Zobacz w Google Maps

Contact Hours:

Pon-pt: 7:00 – 18:00

Check the location of our center

Buses

Access by the following bus lines:

101,102,104,119,122,128,129,143,319,607

Bus stop: Wejherowska (Hala Orbita)

Trams

18,19,24 – tram stop: Wejherowska (Hala Orbita)

Railway

Trains arriving at Wrocław Mikołajów train station

We conduct clinical trials in the following therapeutic areas:

  • Neurology
  • Gastroenterology
  • Dermatology
  • Diabetology
  • Infectious diseases
  • Internal diseases
  • Otorhinolaryngology
  • Allergology
  • Gynecology
  • Pediatrics
  • Sleeping disorders

Center Infrastructure:

We have fully equipped medical and diagnostic offices adapted for conducting clinical trials across various specialties. We prioritize patient comfort and the ergonomics of the research team’s work by providing adequate space, modern solutions, and patient safety ensured through regular equipment inspections.

Diagnostyka

Diagnostics

High-quality endoscopy units, MRI/MRA, computed tomography (CT), OCT, ultrasound/X-ray, and spirometry.

Specjalistyczne urządzenia laboratoryjne

Specialized Laboratory Equipment

• Refrigerator with continuous temperature monitoring
• –20°C freezer with continuous temperature monitoring
• 12-lead ECG
• Scale
• Height measuring device (stadiometer)
• Centrifuge
• Blood pressure monitor
• Thermometers for continuous monitoring of medication storage temperature (2–25°C)

W pełni wyposażone gabinety lekarskie i diagnostyczne

Fully Equipped Medical and Diagnostic Offices

Adapted for conducting studies across various specialties. We focus on patient comfort and the ergonomics of the research team’s work by providing adequate space and modern solutions.

Nowoczesne sale konsultacyjne

Modern Consultation Rooms

for physicians and patients

The center meets the highest storage standards, and restricted access to the Investigational Product ensures full control over research products. All facilities are adapted to the requirements of GCP (Good Clinical Practice)–compliant clinical trials and provide comfort and safety for participants.

Our Specialists:

Our greatest asset is our experienced and dedicated team.

Our staff consists of seasoned specialists who combine clinical expertise with proficiency in conducting clinical trials in accordance with GCP (Good Clinical Practice) and international standards.

Physicians

in the fields of dermatology, neurology, allergology, otolaryngology, and infectious diseases.

Coordinators

clinical trial coordinators with many years of experience in managing documentation, study schedules, and participant care.

Nurses and Pharmacists

Qualified nursing staff and pharmacists trained in clinical protocols and participant safety.

Quality Control:

Our operational structure is based on clearly defined processes that comply with international GCP standards. A strong focus on quality is the foundation of our clinical trials, ensuring full data integrity and patient safety.

Quality Specialist

supervision of quality processes is carried out by a qualified specialist responsible for monitoring compliance with international standards, conducting internal audits, and coordinating corrective actions.

Process Management System

We implement a comprehensive process management system that enables precise mapping and monitoring of all activities related to clinical trials. This ensures full compliance with internal procedures and high operational efficiency.

Internal Training

We regularly conduct specialized quality training to ensure that all members of our team are up to date with the latest requirements and best practices in quality management.

Standard Operating Procedures (SOPs)

At Penta Hospitals Poland, every activity—regardless of its scale—is precisely defined within the Standard Operating Procedures (SOPs). These documents are regularly updated to meet changing regulatory requirements, ensuring operational continuity and consistency at every stage of clinical trial execution.

List of Clinical Trials
Conducted at the Center

Clinical trials – Demetia of an Alzheimer type with agitation

A program aimed at patients experiencing excessive agitation due to physical aggression, excessive motor activity or verbal aggression.

Clinical trials – Upper limb spasticity

Spasticity is abnormal, increased muscle tone, manifested by resistance to muscle stretching. It may be a consequence of an experienced stroke or injury.

Clinical trials – Chronic rhinosinusitis with polyps

Chronic rhinosinusitis with polyps is a condition characterized by long-term inflammation of the nasal and sinus mucosa, which leads to the formation of polyps.

Clinical trials – Atopic dermatitis in adults

Atopic dermatitis is a condition that can impact the comfort of daily life. Unesthetic redness can affect the sick person's appearance, which can lead to lower self-esteem.

Clinical trials – COVID-19

COVID-19 disease caused by SARS-CoV-2 coronavirus mostly affects the respiratory system and can result in serious health consequences for older people and those with existing chronic diseases.

Clinical trials – Alzheimer’s disease

Alzheimer's disease is a degenerative brain condition whose symptoms include progressive memory and behavioural disorders that, over time, completely prevent the patient from correct functioning in everyday life.

Clinical trials – Ulcerative colitis

Ulcerative colitis (UC) is a chronic inflammatory bowel disease that causes inflammation and ulceration in the lining of the large intestine (colon).

Clinical trials – Prostate cancer

Prostate cancer is one of the most common cancers in men, characterized by the development of a malignant tumour in the prostate. Early detection and proper treatment are crucial for improving patient outcomes.

Clinical trials – Prurigo

Prurigo is a chronic skin condition characterized by persistent itching and the appearance of inflamed nodules, often covered with scabs due to scratching. It is a condition associated with an excessive skin response to various stimuli.

Clinical trials – Liver cirrhosis associated with metabolic fatty liver disease

Liver cirrhosis associated with metabolic fatty liver disease is a condition that develops in people who have excessive fat accumulation in their liver cells, even though they do not consume alcohol excessively.

Clinical trial – Crohn’s disease

Crohn's disease is a chronic inflammatory bowel disease that can affect any part of the digestive tract, from the mouth to the anus, although it most often affects the final section of the small intestine (ileum) and the initial part of the large intestine.

Clinical trials – acne inversa

A chronic, inflammatory ski disease characterized by painful abscesses and fistulas, most often in the axillary, groin or submammary areas, which significantly reduces the quality of life and can lead to serious complications and scarring.

Liver fibrosis without cirrhosis in non-alcoholic fatty liver disease

Liver fibrosis is a condition in which scar tissue accumulates in the liver as a result of ongoing damage. At this stage, cirrhosis has not yet developed; however, the condition requires careful monitoring and appropriate diagnosis.

Trial in progress

Clinical trials – Acne

Acne is a common skin condition experienced by both teenagers and adults. It is characterized by blackheads, papules, pustules and purulent cysts, mainly on the face, neck, arms, upper back and chest.

Primary progressive multiple sclerosis (MS) is characterized by a constant progress of the disease from the very beginning. Appearing symptoms of MS do not recede, and they increase with time, leading to the deterioration of neurological function and increased disability.

Primary progressive multiple sclerosis (MS) is characterized by a constant progress of the disease from the very beginning. Appearing symptoms of MS do not recede, and they increase with time, leading to the deterioration of neurological function and increased disability.

Hepatic encephalopathy is a set of neuropsychiatric symptoms caused by a serious liver disease, most often cirrhosis.

Program directed to children and teenagers of 6 to 18 years of age with diagnosed alopecia areata

Vitiligo is a chronic skin disease characterized by the loss of pigment in the skin, leading to the formation of white patches.

Hives is a skin condition characterized by specific wheals, redness, and itching. Hives is often accompanied by swelling known as angioedema.

There is currently no effective vaccine for Lyme disease, but this may soon change.

Completed trial

Cholangitis

Cholangitis is a disease resulting from infection of the bile ducts or an autoimmune reaction. It can occur in acute, chronic, or recurrent purulent forms.

Bullous pemphigoid is the most common subepidermal autoimmune bullous disease. It occurs in older age, after the age of 65, and rarely affects children.

Completed trial

HIV-1 infection

HIV belongs to the retrovirus family and primarily attacks cells of the immune system – white blood cells (CD4 T lymphocytes, monocytes, macrophages) located in the blood, bone marrow, gastrointestinal tract, and central nervous system.

Sleep disorders are a common problem among perimenopausal women. Their occurrence significantly impacts the quality of life and can have serious consequences for a woman's health and well-being.

Nonalcoholic steatohepatitis is the most serious form of non-alcoholic fatty liver disease

Completed trial

Meningococcal vaccine

The study aims to compare the effectiveness of two vaccines against meningococcal diseases types A, C, W-135 and Y – the investigational product MenQuadfi with the commercially available preparation Nimenrix

Women’s urinary tract infection is an infection of the urinary tract, mainly caused by bacteria, that causes inflammation in the lining of the urinary tract, including the bladder and kidneys.

How to participate
in clinical trials

Step 1

Registration

Do you want to participate in a clinical trial? It’s simple. You just need to fill in a short registration form. Our team will contact you for an initial interview to check if the trial is suitable for you. Don’t worry, we will answer all your questions!

Step 2

Appointment with a doctor

After the initial qualification, we will invite you for an appointment with a doctor conducting the trial. The doctor will be available for you to tell you more about the trail, discuss any possible doubts and check the condition of your health.
The appointment is free-of-charge and non-committal.

Step 3

Decision

You are completely free to make your own decision about participating in the trial. After the meeting, you will have time to think through all the information. If you decide to participate, we will sign suitable documents and get you ready for next steps.

Step 4

Participation in the trial

After you make a decision, the actual part of the trial starts. You can always count on our support and use regular consultations.

Clinical Trial
Coordinators
in Wrocław

Piotr Błaszczyszyn - Manager Ośrodka Badań Klinicznych

Piotr Błaszczyszyn

Clinical trial site manager
Default Avatar

Julia Barańczyk

Clinical trial coordinator
Default Avatar

Kamila Piwowarczyk

Clinical trial coordinator

What if you
haven’t found the trial of your interest?

Contact us

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